General Information of Drug (ID: DMF3DZX)

Drug Name
CI-1040 Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
6918454
ChEBI ID
CHEBI:91353
CAS Number
CAS 212631-79-3
TTD Drug ID
DMF3DZX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
U0126 DM31OGF Discovery agent N.A. Investigative [1]
Ro092210 DM2DXHO Discovery agent N.A. Investigative [1]
LLZ16406 DMOGZLU Discovery agent N.A. Investigative [1]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [11]
VX-680 DM93YKJ Solid tumour/cancer 2A00-2F9Z Phase 2 [11]
JNJ-26483327 DMSQ3AZ Solid tumour/cancer 2A00-2F9Z Phase 1 [12]
ISIS-CRP DMQDUG4 Cardiovascular disease BA00-BE2Z Phase 1 [13]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [2]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [2]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [14]
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [15]
BMS-536924 DMXJB4N Discovery agent N.A. Investigative [16]
KN-62 DMLZ89P Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sodium phenylbutyrate DMXLBCQ Spinal muscular atrophy 8B61 Approved [17]
Sotrastaurin acetate DME53YS Renal transplantation NE84 Phase 2 [18]
PMID28460551-Compound-3 DMA1FRM N. A. N. A. Patented [19]
ISIS 3521 DMZFS69 N. A. N. A. Discontinued in Phase 2 [20]
BALANOL DMDLN9E N. A. N. A. Terminated [21]
RO-320432 DMFZ1YW N. A. N. A. Terminated [22]
LY-317644 DMM20PI N. A. N. A. Terminated [23]
Acteoside DM0YHKB Nephritis GB40 Terminated [24]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [25]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [14]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NKP-1339 DM5AWK1 Solid tumour/cancer 2A00-2F9Z Phase 1 [26]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [27]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [27]
7-azaindole derivative 1 DMQL5B7 N. A. N. A. Patented [27]
7-azaindole derivative 5 DMV3H98 N. A. N. A. Patented [27]
PMID25991433-Compound-P6 DMNDVC9 N. A. N. A. Patented [27]
PMID25991433-Compound-J3 DM17P3F N. A. N. A. Patented [27]
PMID25991433-Compound-P1 DMD8AX6 N. A. N. A. Patented [27]
PMID25991433-Compound-O3 DMVOWS5 N. A. N. A. Patented [27]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [27]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Netarsudil DM0LPI9 Open-angle glaucoma 9C61 Approved [28]
SAR-407899 DMF95KD Diabetic nephropathy GB61.Z Phase 2 [29]
H-1152 DM8XH3S Pulmonary arterial hypertension BB01.0 Phase 2 [30]
INS-117548 DMA46DO Glaucoma/ocular hypertension 9C61 Phase 1 [31]
GSK269962A DM5I2HL Inflammation 1A00-CA43.1 Clinical trial [32]
PMID28048944-Compound-19 DMPT3V9 N. A. N. A. Patented [33]
PMID28048944-Compound-3 DM1BN74 N. A. N. A. Patented [33]
PMID28048944-Compound-7 DMXZ368 N. A. N. A. Patented [33]
PMID28048944-Compound-4 DMJAUWG N. A. N. A. Patented [33]
PMID28048944-Compound-5 DMAB987 N. A. N. A. Patented [33]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [1]
SB 235699 DMNH8XU Psoriasis vulgaris EA90 Discontinued in Phase 1 [1]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [2]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [2]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [14]
KN-62 DMLZ89P Discovery agent N.A. Investigative [2]
Ro31-8220 DMDJLF0 Discovery agent N.A. Investigative [2]
STAUROSPORINONE DMU2H4K Discovery agent N.A. Investigative [2]
KT-5720 DM9J50F Discovery agent N.A. Investigative [2]
L-779450 DM51B74 Discovery agent N.A. Investigative [34]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BVD-523 DMNB4XK Melanoma 2C30 Phase 2 [35]
HH2710 DM0C5MV Solid tumour/cancer 2A00-2F9Z Phase 1/2 [36]
ASTX029 DMVZXIA Solid tumour/cancer 2A00-2F9Z Phase 1/2 [37]
VAN-10-4-eluting stent DM3ZW6A Artery stenosis BD52 Phase 1 [38]
GDC-0994 DMFC2OY Solid tumour/cancer 2A00-2F9Z Phase 1 [39]
JSI-1187 DMVJWBS Solid tumour/cancer 2A00-2F9Z Phase 1 [40]
LY3214996 DMFDAY7 Solid tumour/cancer 2A00-2F9Z Phase 1 [41]
CHIR-99021 DMB8MNU Allergic inflammation 4A80-4A85 Patented [42]
COR-D DMLXMCB T-cell leukaemia 2A90 Preclinical [43]
SB220025 DMSBUET Arthritis FA20 Terminated [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Checkpoint kinase-1 (CHK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY2603618 DMCXRZF Pancreatic cancer 2C10 Phase 2 [45]
UCN-01 DMUNJZB Non-small-cell lung cancer 2C25.Y Phase 2 [46]
SCH-900776 DM67EMK Solid tumour/cancer 2A00-2F9Z Phase 2 [47]
LY2606368 DM4XMF7 Ovarian cancer 2C73 Phase 2 [41]
LY2880070 DMADEHZ Solid tumour/cancer 2A00-2F9Z Phase 1/2 [48]
RG7741 DMK6P9J Lymphoma 2A80-2A86 Phase 1 [49]
GDC-0425 DMDZ26X Lymphoma 2A80-2A86 Phase 1 [50]
AZD7762 DM1FW0C Solid tumour/cancer 2A00-2F9Z Phase 1 [51]
MK-8776 DMAS1RB Hodgkin lymphoma 2B30 Phase 1 [52]
Diamidothiazole derivative 1 DM02V5Q N. A. N. A. Patented [53]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RO-316233 DMAGLPW Discovery agent N.A. Investigative [2]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [2]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [14]
KN-62 DMLZ89P Discovery agent N.A. Investigative [2]
CGP-57380 DMFPOUC Discovery agent N.A. Investigative [13]
GSK-650394 DMNRP2L Prostate cancer 2C82.0 Investigative [54]
⏷ Show the Full List of 6 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ozagrel DMIGKA1 Xerophthalmia 5B55.Y Phase 4 [55]
Losmapimod DMIL37Z Acute coronary syndrome BA41 Phase 3 [55]
VX-702 DMKJDR6 Coronary artery disease BA80 Phase 2a [56]
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [1]
Dilmapimod DMBYJ92 Acute lung injury NB32.3 Phase 2 [55]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [27]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [27]
PMID25991433-Compound-L2 DM58UO9 N. A. N. A. Patented [27]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [27]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [27]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Capivasertib DM9SKW8 Breast cancer 2C60-2C65 Approved [41]
Enzastaurin DM5H0R9 Diffuse large B-cell lymphoma 2A81 Phase 3 [41]
GDC-0068 DMWBZJD Breast cancer 2C60-2C65 Phase 3 [41]
CI-1033 DMSI8N3 Lymphoma 2A80-2A86 Phase 2 [11]
CMX-2043 DMPSCVY Cardiac disease BA00-BE2Z Phase 2 [57]
ARQ 092 DM5WK0J Proteus syndrome LD2C Phase 2 [58]
GSK2110183 DMZHB37 leukaemia 2A60-2B33 Phase 2 [59]
RX-0201 DMTBAV3 Pancreatic cancer 2C10 Phase 2 [60]
PTX-200 DM0ZIT2 Breast cancer 2C60-2C65 Phase 2 [41]
Triciribine prodrug DMBN1XS Solid tumour/cancer 2A00-2F9Z Phase 1/2 [59]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AMO-02 DMJRU3A Myotonic dystrophy 8C71.0 Phase 2/3 [61]
LY2090314 DMTBFE4 Acute myeloid leukaemia 2A60 Phase 2 [62]
Lithium DMZ3OU6 Bipolar disorder 6A60 Phase 2 [63]
Tideglusib DME4LA1 Alzheimer disease 8A20 Phase 2 [64]
9-ING-41 DM57TY3 Myelofibrosis 2A20.2 Phase 2 [65]
Neu-120 DMXKOUC Parkinson disease 8A00.0 Phase 1/2 [66]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [67]
CHIR-99021 DMB8MNU Allergic inflammation 4A80-4A85 Patented [42]
TDZD-8 DMG6Q45 Malignant glioma 2A00.0 Patented [68]
AR-A014418 DMUPN01 Ovarian cancer 2C73 Patented [69]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
URMC-099 DMCJXWK Discovery agent N.A. Investigative [70]
U0126 DM31OGF Discovery agent N.A. Investigative [1]
Ro092210 DM2DXHO Discovery agent N.A. Investigative [1]
LLZ16407 DM783BP Discovery agent N.A. Investigative [1]
Drug(s) Targeting MAP kinase p38 (MAPK12)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SM-101 DMFX9O6 Idiopathic thrombocytopenic purpura 3B64.10 Approved (orphan drug) [71]
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [72]
ARRY-797 DMJ48AB Dilated cardiomyopathy BC43.0 Phase 2 [73]
KC706 DMBX6C7 Cardiovascular disease BA00-BE2Z Discontinued in Phase 2 [74]
SB 235699 DMNH8XU Psoriasis vulgaris EA90 Discontinued in Phase 1 [75]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [2]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [2]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [14]
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [15]
KN-62 DMLZ89P Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
M2698 DM3PVBJ Solid tumour/cancer 2A00-2F9Z Phase 1 [41]
NNI-362 DMPCV65 Alzheimer disease 8A20 Phase 1 [76]
PF-4708671 DMO0892 Ulcerative colitis DD71 Clinical trial [77]
PMID27410995-Compound-Figure3c DMDQMZT N. A. N. A. Patented [78]
Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1 DM6O2Q9 N. A. N. A. Patented [78]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [2]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X Discovery agent N.A. Investigative [79]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [14]
KN-62 DMLZ89P Discovery agent N.A. Investigative [2]
Ro31-8220 DMDJLF0 Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [80]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [81]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [82]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [83]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [84]
Quercetin DM3NC4M Obesity 5B81 Approved [85]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [86]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [87]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [88]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [89]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [90]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [91]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [92]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [93]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [94]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [94]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [95]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [96]
Capsaicin DMGMF6V Back pain ME84.Z Approved [97]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [98]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [90]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [91]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [96]
Ritonavir DMU764S Human immunodeficiency virus infection 1C62 Approved [96]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [99]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [100]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [101]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [102]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [103]
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [104]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 3A7 (CYP3A7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [105]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [102]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [100]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [106]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [107]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [108]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [109]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [110]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [111]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [112]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Calcipotriol DM03CP7 Psoriasis EA90 Approved [113]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [114]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [80]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [115]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [116]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [114]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [117]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [118]
Quercetin DM3NC4M Obesity 5B81 Approved [119]
Fluoxetine DM3PD2C Bipolar depression Approved [114]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Tumor protein p73 (TP73)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [120]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [121]
Etretinate DM2CZFA Keratosis ED56 Approved [122]
Quercetin DM3NC4M Obesity 5B81 Approved [123]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [124]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [125]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [126]
Menthol DMG2KW7 Back pain ME84.Z Approved [127]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [128]
Bexarotene DMOBIKY Cutaneous T-cell lymphoma 2B01 Approved [122]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [129]
Gefitinib DM15F0X Colon adenocarcinoma Approved [130]
Erlotinib DMCMBHA Adrenal gland neoplasm Approved [131]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [132]
Gemcitabine DMSE3I7 Anterior urethra cancer Approved [133]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [134]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [135]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [136]
Selenium DM25CGV N. A. N. A. Approved [137]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [138]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [139]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [140]
Etretinate DM2CZFA Keratosis ED56 Approved [141]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [142]
Methotrexate DM2TEOL Anterior urethra cancer Approved [143]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [144]
Quercetin DM3NC4M Obesity 5B81 Approved [145]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [146]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [147]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [148]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [149]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [150]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [151]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [152]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [153]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [154]
Secobarbital DM14RF5 Epilepsy 8A60-8A68 Approved [155]
Gefitinib DM15F0X Colon adenocarcinoma Approved [6]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [156]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [157]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Catenin beta-1 (CTNNB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [158]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [159]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [160]
Quercetin DM3NC4M Obesity 5B81 Approved [161]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [162]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [163]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [164]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [165]
Testosterone DM7HUNW Hot flushes GA30 Approved [5]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [166]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Caspase-3 (CASP3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sevoflurane DMC9O43 Anaesthesia 9A78.6 Approved [167]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [168]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [169]
Cidofovir DMA13GD Cytomegalovirus infection 1D82 Approved [170]
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [171]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [172]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [173]
Mannitol DMSCDY9 Bronchiectasis CA24 Approved [174]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [175]
Aprepitant DM053KT Depression 6A70-6A7Z Approved [176]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [177]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [178]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [179]
Ethacrynic acid DM60QMR Edema MG29 Approved [180]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [181]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [182]
Testosterone DM7HUNW Hot flushes GA30 Approved [183]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [184]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [185]
Menthol DMG2KW7 Back pain ME84.Z Approved [127]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Caveolin-1 (CAV1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [186]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [80]
Gefitinib DM15F0X Colon adenocarcinoma Approved [6]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [187]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [188]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [189]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [190]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [191]
Acocantherin DM7JT24 Atrial fibrillation BC81.3 Approved [192]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [102]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sequestosome-1 (SQSTM1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [193]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [194]
Gefitinib DM15F0X Colon adenocarcinoma Approved [195]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [196]
Trametinib DM2JGQ3 Melanoma 2C30 Approved [197]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [198]
Methotrexate DM2TEOL Anterior urethra cancer Approved [143]
Quercetin DM3NC4M Obesity 5B81 Approved [119]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [199]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [200]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [201]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [202]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [203]
Leflunomide DMR8ONJ Arthritis FA20 Approved [204]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [184]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [205]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [206]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [207]
Famotidine DMRL3AB Gastric ulcer DA60 Approved [208]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [209]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Checkpoint kinase-1 (CHK1) TTTU902 CHK1_HUMAN Inhibitor [2]
Extracellular signal-regulated kinase 2 (ERK2) TT4TQBX MK01_HUMAN Inhibitor [2]
Glycogen synthase kinase-3 beta (GSK-3B) TTRSMW9 GSK3B_HUMAN Inhibitor [2]
LCK tyrosine protein kinase (LCK) TT860QF LCK_HUMAN Inhibitor [2]
MAP kinase p38 (MAPK12) TTYT93M MK12_HUMAN Inhibitor [2]
MAPK/ERK kinase kinase 1 (MAP3K1) TTQBCEJ M3K1_HUMAN Inhibitor [1]
MAPK/ERK kinase kinase 2 (MAP3K2) TTK1N5G M3K2_HUMAN Inhibitor [1]
Protein kinase C alpha (PRKCA) TTFJ8Q1 KPCA_HUMAN Inhibitor [2]
RAC-alpha serine/threonine-protein kinase (AKT1) TTWTSCV AKT1_HUMAN Inhibitor [2]
Rho-associated protein kinase 1 (ROCK1) TTZN7RP ROCK1_HUMAN Inhibitor [2]
Ribosomal protein S6 kinase beta-1 (S6K1) TTG0U4H KS6B1_HUMAN Inhibitor [2]
Serine/threonine-protein kinase Sgk1 (SGK1) TTTV8EJ SGK1_HUMAN Inhibitor [2]
Stress-activated protein kinase 2a (p38 alpha) TTQBR95 MK14_HUMAN Inhibitor [2]
Stress-activated protein kinase 2b (p38 beta) TT73U6C MK11_HUMAN Inhibitor [2]
Stress-activated protein kinase JNK1 (JNK1) TT0K6EO MK08_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Gene/Protein Processing [3]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Protein Interaction/Cellular Processes [4]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Post-Translational Modifications [5]
Caveolin-1 (CAV1) OTEZUR1L CAV1_HUMAN Gene/Protein Processing [6]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [7]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Gene/Protein Processing [7]
Cytochrome P450 3A7 (CYP3A7) OTTCDHHM CP3A7_HUMAN Gene/Protein Processing [7]
Dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1) OT4Y9NQI MP2K1_HUMAN Gene/Protein Processing [8]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Post-Translational Modifications [9]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Gene/Protein Processing [10]

References

1 Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
2 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
3 ERK kinase inhibition stabilizes the aryl hydrocarbon receptor: implications for transcriptional activation and protein degradation. J Biol Chem. 2005 Feb 11;280(6):4350-9.
4 The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines. J Pharmacol Exp Ther. 2006 Jan;316(1):456-65. doi: 10.1124/jpet.105.091454. Epub 2005 Oct 20.
5 Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro. 2017 Apr;40:324-335. doi: 10.1016/j.tiv.2017.01.019. Epub 2017 Feb 2.
6 Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
7 U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells. Arch Toxicol. 2014 Dec;88(12):2243-59.
8 Enzyme kinetics and binding studies on inhibitors of MEK protein kinase. Biochemistry. 2008 Apr 29;47(17):5017-27. doi: 10.1021/bi701811x. Epub 2008 Apr 5.
9 Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006 Mar;96(2):131-46. doi: 10.1007/s10549-005-9070-2. Epub 2005 Oct 27.
10 Cigarette smoke components induce matrix metalloproteinase-1 in aortic endothelial cells through inhibition of mTOR signaling. Toxicol Sci. 2011 Oct;123(2):542-9. doi: 10.1093/toxsci/kfr181. Epub 2011 Jul 8.
11 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
12 National Cancer Institute Drug Dictionary (drug id 596693).
13 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
14 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
15 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
16 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
17 Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.
18 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
19 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
20 Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.Lung Cancer.2006 May;52(2):173-80.
21 Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
22 Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
23 Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
24 Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
25 Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
26 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
27 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
28 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
29 The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9.
30 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
31 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
32 Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
33 Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
34 The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
35 DOI: 10.1158/1538-7445.AM2015-4693
36 Clinical pipeline report, company report or official report of HaiHe Biopharma.
37 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
38 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
39 ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
40 National Cancer Institute Drug Dictionary (drug name JSI1187).
41 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
42 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
43 Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
44 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
45 Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
46 Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
47 Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
48 A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
49 National Cancer Institute Drug Dictionary (drug id 730054).
50 Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
51 Clinical pipeline report, company report or official report of AstraZeneca (2009).
52 Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095.
53 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
54 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8040).
55 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
56 Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
57 Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
58 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
59 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
60 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
61 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
62 Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
63 The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
64 Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
65 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
66 Company report (Neurim Pharmaceuticals)
67 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
68 Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
69 Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
70 Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48.
71 Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
72 P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22.
73 Array BioPharmas ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs
74 KC706, an Oral p38 MAP Kinase Inhibitor, Increases HDL-C. Circulation. 2007;116:II_126.
75 Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem. 2003 Dec 18;46(26):5651-62.
76 Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease. Stem Cell Res Ther. 2021 Jan 13;12(1):59.
77 Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55.
78 Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.
79 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
80 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
81 Oxidative stress modulates expression of immune checkpoint genes via activation of AhR signaling. Toxicol Appl Pharmacol. 2022 Dec 15;457:116314. doi: 10.1016/j.taap.2022.116314. Epub 2022 Nov 9.
82 Profiling of enantiopure drugs towards aryl hydrocarbon (AhR), glucocorticoid (GR) and pregnane X (PXR) receptors in human reporter cell lines. Chem Biol Interact. 2014 Feb 5;208:64-76. doi: 10.1016/j.cbi.2013.11.018. Epub 2013 Dec 6.
83 Involvement of cytoskeleton in AhR-dependent CYP1A1 expression. Curr Drug Metab. 2006 Apr;7(3):301-13. doi: 10.2174/138920006776359310.
84 Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2008 Mar 1;122(5):990-8.
85 Quercetin, quercetin glycosides and taxifolin differ in their ability to induce AhR activation and CYP1A1 expression in HepG2 cells. Phytother Res. 2012 Nov;26(11):1746-52.
86 Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway. Chem Res Toxicol. 2015 May 18;28(5):907-18.
87 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
88 Expression and inducibility of cytochrome P450s (CYP1A1, 2B6, 2E1, 3A4) in human cord blood CD34(+) stem cell-derived differentiating neuronal cells. Toxicol Sci. 2012 Oct;129(2):392-410.
89 Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.
90 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
91 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
92 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
93 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
94 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
95 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
96 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
97 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
98 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
99 Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005 Jul;33(7):1074-81. doi: 10.1124/dmd.104.002279. Epub 2005 Apr 8.
100 Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
101 Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci. 2017;42(3):343-348.
102 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
103 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
104 Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013 Feb;41(2):281-90.
105 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
106 Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
107 Human drug metabolism genes in parathion-and estrogen-treated breast cells. Int J Mol Med. 2007 Dec;20(6):875-81.
108 Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol. 2009 Feb 1;234(3):345-60.
109 Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
110 Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther. 2005 Aug;314(2):626-35. doi: 10.1124/jpet.105.086504. Epub 2005 Apr 21.
111 Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol. 2010 Nov;161(5):1059-69. doi: 10.1111/j.1476-5381.2010.00946.x.
112 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
113 Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
114 A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
115 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
116 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
117 Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
118 Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
119 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
120 The role of RelA (p65) threonine 505 phosphorylation in the regulation of cell growth, survival, and migration. Mol Biol Cell. 2011 Sep;22(17):3032-40. doi: 10.1091/mbc.E11-04-0280. Epub 2011 Jul 7.
121 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
122 Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
123 Quercetin and Its Fermented Extract as a Potential Inhibitor of Bisphenol A-Exposed HT-29 Colon Cancer Cells' Viability. Int J Mol Sci. 2023 Mar 15;24(6):5604. doi: 10.3390/ijms24065604.
124 Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 2010 Sep;27(3):833-42. doi: 10.1007/s12032-009-9294-9. Epub 2009 Sep 10.
125 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
126 Nuclear and Mitochondrial DNA Methylation Patterns Induced by Valproic Acid in Human Hepatocytes. Chem Res Toxicol. 2017 Oct 16;30(10):1847-1854. doi: 10.1021/acs.chemrestox.7b00171. Epub 2017 Sep 13.
127 Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
128 Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. J Biol Chem. 2007 Oct 12;282(41):29847-54.
129 Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J Med Chem. 2011 Mar 10;54(5):1347-55. doi: 10.1021/jm101396q. Epub 2011 Feb 15.
130 Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
131 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
132 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
133 A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
134 Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. Oncology. 2007;73(1-2):104-11. doi: 10.1159/000120998. Epub 2008 Mar 13.
135 Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
136 Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
137 Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
138 Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery. 2005 Sep;138(3):415-21. doi: 10.1016/j.surg.2005.06.030.
139 Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
140 Oxidative Stress-Protective and Anti-Melanogenic Effects of Loliolide and Ethanol Extract from Fresh Water Green Algae, Prasiola japonica. Int J Mol Sci. 2018 Sep 18;19(9):2825. doi: 10.3390/ijms19092825.
141 The effects of a novel synthetic retinoid, seletinoid G, on the expression of extracellular matrix proteins in aged human skin in vivo. Clin Chim Acta. 2005 Dec;362(1-2):161-9. doi: 10.1016/j.cccn.2005.06.016. Epub 2005 Aug 1.
142 Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1beta in human tendon-derived cells. A potential mechanism of fluoroquinolone-induced tendinopathy. Arthritis Rheum. 2002 Nov;46(11):3034-40. doi: 10.1002/art.10617.
143 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
144 Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. Arterioscler Thromb Vasc Biol. 2007 May;27(5):1043-9. doi: 10.1161/ATVBAHA.107.139881. Epub 2007 Feb 15.
145 Quercetin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells through extracellular signal-regulated kinase. Arch Biochem Biophys. 2001 Jul 1;391(1):72-8. doi: 10.1006/abbi.2001.2402.
146 Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: implication for the adverse effects of cyclooxygenase-2 inhibitors. Clin Pharmacol Ther. 2006 Apr;79(4):303-15. doi: 10.1016/j.clpt.2005.12.306.
147 Interaction between the aryl hydrocarbon receptor and retinoic acid pathways increases matrix metalloproteinase-1 expression in keratinocytes. J Biol Chem. 2004 Jun 11;279(24):25284-93. doi: 10.1074/jbc.M402168200. Epub 2004 Apr 9.
148 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
149 Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
150 Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
151 Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
152 Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
153 Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
154 Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
155 Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
156 Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
157 SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
158 Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
159 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
160 Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008 Mar 31;583(1):26-31. doi: 10.1016/j.ejphar.2007.12.034. Epub 2008 Feb 5.
161 Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
162 Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012 Jan 2;348(1):260-9. doi: 10.1016/j.mce.2011.09.002. Epub 2011 Sep 6.
163 Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res. 2008 Nov;32(11):1674-83. doi: 10.1016/j.leukres.2008.03.039. Epub 2008 May 15.
164 Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006 Oct 19;25(49):6447-56. doi: 10.1038/sj.onc.1209658. Epub 2006 Jul 31.
165 Benzene metabolite hydroquinone induces apoptosis of bone marrow mononuclear cells through inhibition of -catenin signaling. Toxicol In Vitro. 2018 Feb;46:361-369. doi: 10.1016/j.tiv.2017.08.018. Epub 2017 Sep 5.
166 Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
167 Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
168 [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
169 Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
170 Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
171 Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
172 Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
173 Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
174 Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
175 mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
176 Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
177 Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers (Basel). 2020 Sep 27;12(10):2774. doi: 10.3390/cancers12102774.
178 Inhibition of phosphatidylinostol 3-kinase uncouples H2O2-induced senescent phenotype and cell cycle arrest in normal human diploid fibroblasts. Exp Cell Res. 2004 Aug 1;298(1):188-96. doi: 10.1016/j.yexcr.2004.04.012.
179 Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice. Cancer. 2008 Feb 1;112(3):596-607. doi: 10.1002/cncr.23223.
180 Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Sci. 2003 Oct;94(10):886-93.
181 Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
182 Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
183 Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle. 2010 Apr 15;9(8):1629-38. doi: 10.4161/cc.9.8.11487. Epub 2010 Apr 15.
184 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
185 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
186 -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
187 The protective effect of quercetin against oxidative stress in the human RPE in vitro. Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1712-20. doi: 10.1167/iovs.07-0477.
188 Nitric oxide regulates lung carcinoma cell anoikis through inhibition of ubiquitin-proteasomal degradation of caveolin-1. J Biol Chem. 2009 Oct 9;284(41):28476-28484. doi: 10.1074/jbc.M109.050864. Epub 2009 Aug 25.
189 Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
190 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
191 Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
192 Ouabain impairs cell migration, and invasion and alters gene expression of human osteosarcoma U-2 OS cells. Environ Toxicol. 2017 Nov;32(11):2400-2413. doi: 10.1002/tox.22453. Epub 2017 Aug 10.
193 Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
194 Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021 Oct;17(10):2783-2799. doi: 10.1080/15548627.2020.1841953. Epub 2020 Nov 9.
195 Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells. Clin Lung Cancer. 2015 Sep;16(5):e55-66. doi: 10.1016/j.cllc.2015.03.006. Epub 2015 Apr 2.
196 MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
197 Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma. Br J Dermatol. 2019 Feb;180(2):346-356. doi: 10.1111/bjd.17333. Epub 2018 Nov 25.
198 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
199 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
200 Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
201 Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006 Oct;33(7):875-82. doi: 10.1016/j.nucmedbio.2006.07.004.
202 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
203 A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
204 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
205 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
206 Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells initro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology. 2017 Jun;152(8):2022-2036.
207 Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
208 Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010 Sep 30;467(7315):596-9. doi: 10.1038/nature09454.
209 Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology. 2007;85(1):45-53. doi: 10.1159/000100508. Epub 2007 Mar 5.